Your browser doesn't support javascript.
loading
Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease.
van Linschoten, Reinier Cornelis Anthonius; Huberts, Anouk Sjoukje; van Leeuwen, Nikki; Hazelzet, Jan Antonius; van der Woude, Janneke; West, Rachel Louise; van Noord, Desirée.
Afiliação
  • van Linschoten RCA; Department of Gastroenterology & Hepatology, Franciscus Gasthuis & Vlietland, P.O Box 10900, Rotterdam 3004BA, Netherlands.
  • Huberts AS; Department of Gastroenterology & Hepatology, Erasmus MC, Rotterdam, Netherlands.
  • van Leeuwen N; Department of Quality and Patientcare, Erasmus MC, Rotterdam, Zuid-Holland, Netherlands.
  • Hazelzet JA; Department of Public Health, Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands.
  • van der Woude J; Department of Public Health, Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands.
  • West RL; Department of Gastroenterology & Hepatology, Erasmus MC, Rotterdam, Netherlands.
  • van Noord D; Department of Gastroenterology & Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands.
Therap Adv Gastroenterol ; 16: 17562848231202159, 2023.
Article em En | MEDLINE | ID: mdl-37877105
ABSTRACT

Background:

The International Consortium for Health Outcomes Measurement has selected the self-administered comorbidity questionnaire (SCQ) to adjust case-mix when comparing outcomes of inflammatory bowel disease (IBD) treatment between healthcare providers. However, the SCQ has not been validated for use in IBD patients.

Objectives:

We assessed the validity of the SCQ for measuring comorbidities in IBD patients.

Design:

Cohort study.

Methods:

We assessed the criterion validity of the SCQ for IBD patients by comparing patient-reported and clinician-reported comorbidities (as noted in the electronic health record) of the 13 diseases of the SCQ using Cohen's kappa. Construct validity was assessed using the Spearman correlation coefficient between the SCQ and the Charlson Comorbidity Index (CCI), clinician-reported SCQ, quality of life, IBD-related healthcare and productivity costs, prevalence of disability, and IBD disease activity. We assessed responsiveness by correlating changes in the SCQ with changes in healthcare costs, productivity costs, quality of life, and disease activity after 15 months.

Results:

We included 613 patients. At least fair agreement (κ > 0.20) was found for most comorbidities, but the agreement was slight (κ < 0.20) for stomach disease [κ = 0.19, 95% CI (-0.03; 0.41)], blood disease [κ = 0.02, 95% CI (-0.06; 0.11)], and back pain [κ = 0.18, 95% CI (0.11; 0.25)]. Correlations were found between the SCQ and the clinician-reported SCQ [ρ = 0.60, 95% CI (0.55; 0.66)], CCI [ρ = 0.39, 95% CI (0.31; 0.45)], the prevalence of disability [ρ = 0.23, 95% CI (0.15; 0.32)], and quality of life [ρ = -0.30, 95% CI (-0.37; -0.22)], but not between the SCQ and healthcare or productivity costs or disease activity (|ρ| ⩽ 0.2). A change in the SCQ after 15 months was not correlated with a change in any of the outcomes.

Conclusion:

The SCQ is a valid tool for measuring comorbidity in IBD patients, but face and content validity should be improved before being used to correct case-mix differences.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Therap Adv Gastroenterol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Therap Adv Gastroenterol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda